164 related articles for article (PubMed ID: 3162176)
1. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
Wenderoth UK; Jacobi GH
Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
[TBL] [Abstract][Full Text] [Related]
2. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
[No Abstract] [Full Text] [Related]
3. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
[TBL] [Abstract][Full Text] [Related]
4. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
5. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
6. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
9. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
Baranowska B
Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
[No Abstract] [Full Text] [Related]
10. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
Lukkarinen O; Hammond GL; Kontturi M; Vihko R
Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
[TBL] [Abstract][Full Text] [Related]
13. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone analogues for prostate cancer: untoward side effects of high-dose regimens acquire a therapeutical dimension.
Jacobi GH; Wenderoth UK
Eur Urol; 1982; 8(3):129-34. PubMed ID: 6281023
[TBL] [Abstract][Full Text] [Related]
15. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
Waxman JH; Hendry WF; Whitfield HN; Oliver RT
Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
[TBL] [Abstract][Full Text] [Related]
16. Management of metastatic prostatic cancer.
Paulson DF
Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
[TBL] [Abstract][Full Text] [Related]
17. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
[TBL] [Abstract][Full Text] [Related]
18. LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.
Jacobi GH
Recent Results Cancer Res; 1990; 118():174-85. PubMed ID: 2146724
[No Abstract] [Full Text] [Related]
19. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
20. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
